Edwards’ Sapien 3 Artificial Heart Valve For High Risk Patients
Repeated failure of the bio-prosthetic aortic valve or Mitral valve, which raises the chances of fatality or severe complications in patients of symptomatic heart disease, has lead to a new breakthrough in artificial valve technology.
The US Food and Drug Administration (FDA) recently approved the use of Edward Lifescience LLC’s Sapien 3 Transcatheter Heart Valve, which will replace the Aortic or Mitral valve in case of failure. The use of the new valve has also been expanded to high-risk patients by the FDA, giving a new lease on life for patients of symptomatic heart disease.
As per experts in cardiovascular devices at the FDA, this is the first time any regulatory agency was approving a transcatheter heart valve as a valve-in-valve treatment to replace the bio-prosthetic mitra...